US Supreme Court addresses patent eligibility of isolated DNA and cDNA in Myriad V

Association for Molecular Pathology v Myriad Genetics, Inc, 133 S Ct 2107 (US 2013) (‘Myriad V’), US Supreme Court, 13 June 2013 Abstract The US Supreme Court unanimously ruled that Myriad Genetics, Inc’s claims to isolated, naturally occurring human DNA sequences are not patent-eligible, but that Myriad’s claims to cDNA, which necessarily includes manipulated DNA […]

In The Press:
IP Watch Turns To Partner Charles Macedo For Comments from the Corporate IP Counsel Meeting

A wide variety of metrics of valuation were listed, taking both a qualitative or quantitative approach. Examples listed were: how often the patent is cited; who cited; length of claims; strength/validity of claims; priority date; geographic coverage; pendency of application; competing technologies; development stage; right to produce/sell/use; scope of areas of application; size of market; […]

ARE Patent Law Alert: Developments in FRAND: Presidential Veto Prevents ITC Exclusion of Apple Devices Found to Infringe Samsung Standards Essential Patents on Public Interest Grounds

(August 7, 2013). On August 3, 2013 the Obama administration overturned a U.S. International Trade Commission Order barring imports of Apple’s iPhone 4 and iPad 2 that had been found by the ITC to infringe a standards-essential Samsung patent (view file). Exercising its power to veto an ITC Exclusion Order for the first time since […]